Studying the risks of drug provision for breast cancer patients in the public procurement system of Russia

Background. Breast cancer is a socially significant disease. In Russia, the drug provision of breast cancer patients at all stages of treatment is carried out within the public procurement (PP) system. A systematic risk analysis of the PPs of antitumor drugs is an essential requirement for the safety and effectiveness of chemotherapy treatment.
Objective: Identification of the main stages in the PPs of antitumor drugs used in breast cancer therapy; assessment of possible risks at each stage, development of a heat map for the studied risks.
Material and methods. The methods of content and comparative analysis of scientific publications, legislative acts and protocols of open auctions, requests for quotations from four Russian oncological hospitals in the Southern and Central Federal Districts were used. In order to obtain a quantitative estimate of the overall risk for each group and to construct a risk heat map, the severity of consequences and the probability of risk occurrence were combined in a multiplicative model.
Results. The key stages in the PPs of antitumor drugs were established to include tender planning, PP realization, government contract conclusion, and its execution. At the stage of tender planning, the following groups of the risks were identified: the risk of delaying the implementation of innovative chemotherapy treatment regimens into the real clinical practice; the risk of prescribing the chemotherapy treatment regimens classified as an increased risk of adverse reactions; the risk of excessive uniformity and/or variety of dosage regiments. At the stage of PP realization and contract conclusion, the risks are related to a cancellation of the purchase and forced procurements of more affordable analogues. The stage of contract execution involves the risks of reduced patient compliance due to the transfer of tablet drug forms to the ambulatory release; emergence of an urgent need for particular drugs due to changes in the treatment strategy; reduced effectiveness of thermolabile drugs due to a violation of the temperature regime of their transportation. The risk of forced procurements of more affordable analogues was rated as the highest level, while the risks of purchase cancellation and the emergence of an urgent need for drugs were ranked among the lowest.
Conclusion. The results obtained may serve as a basis for improving the risk-based approach to PPs through minimizing negative consequences for patients, hospitals and the entire healthcare system.

1. Kaprin A.D., Starinsky V.V., Shakhzadova A.O. (Eds) The state of oncological care for the population of Russia in 2024. Мoscow: Herzen Moscow Oncology Research Institute – branch of National Medical Research Radiological Centre; 2025: 275 pp. (in Russ.).

2. Tsvetkova A., Mihaylova S., Kamusheva M. Social and economic burden of breast cancer in the North East region of Bulgaria. Expert Rev Pharmacoecon Outcomes Res. 2021; 21 (6): 1203–9. https://doi.org/10.1080/14737167.2021.1947247.

3. Ignatyeva V.I., Gretsova O.P., Stenina M.B., et al. Social and economic burden of breast cancer in the Russian Federation. Medical Technologies. Assessment and Choice. 2016; 4: 32–49 (in Russ.).

4. Rubricator of clinical guidelines. Breast сancer. 2021. Available at: https://cr.minzdrav.gov.ru/preview-cr/379_4 (in Russ.) (accessed 11.08.2025).

5. Unified information system in the field of procurement. Aailable at: https://zakupki.gov.ru/epz/main/public/home.html (in Russ.) (accessed 13.08.2025).

6. Mozoleva S.S., Ledyaev M.Y., Shephatova E.I., Ivanov Y.V. Changes in the myocardium in adolescents with masked hypertension. Journal of Volgograd State Medical University. 2017; 14 (4): 87–9 (in Russ.). https://doi.org/10.19163/1994-9480-2017-4(64)-87-89.

7. Orlov A.I., Tsisarskiy A.D. Risk assessment method in creating spacerocket technology. Herald of the Bauman Moscow State Technical University. Series Mechanical Engineering. 2017; 2: 99–107. https://doi.org/10.18698/0236-3941-2017-2-99-107.

8. Frolova O.A., Makarychev V.A., Yashina I.D. Topical issues of organizing the process of procurement of goods, works and services by budgetary organizations in the current economic situation, aimed at ensuring the economic security of the country. The Eurasian Scientific Journal. 2023; 15 (s1): 61FAVN123 (in Russ.).

9. Ayash L.J., Elias A., Wheeler C., et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clini Oncol. 1994; 12 (1): 37–44. https://doi.org/10.1200/JCO.1994.12.1.37.

10. Biganzoli L., Cufer T., Bruning P., et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol. 2002; 20 (14): 3114–21. https://doi.org/10.1200/JCO.2002.11.005.

11. Mashchelueva A.Yu., Abramov M.E. Current aspects of the use of carboplatin in modern chemotherapy of solid tumors. Effective Pharmacotherapy in Oncology, Hematology and Radiology. 2010; 2: 44–67.

12. Zolotovskaya I.A., Davydkin I.L., Lokshtanova T.M., Orlov A.E. Clinical signs of chemotherapy-induced neuropathy in cancer patients and pharmacotherapy correction options. Archive of Internal Medicine. 2018; 8 (2): 137–45 (in Russ.). https://doi.org/10.20514/2226-6704-2018-8-2-137-144.

13. Rubricator of clinical guidelines. Malignant neoplasm of the bronchi and lung. 2022. Available at: https://cr.minzdrav.gov.ru/preview-cr/30_4 (in Russ.) (accessed 20.08.2025).

14. Gorbunova V.A., Orel N.F., Borisova T.A., et al. Possibilities of using taxotere in various solid tumors. Journal of Modern Oncology. 2002; 4 (4): 177–81 (in Russ.).

15. Borisova E.I., Gutorov S.P., Vyshinskaya G.V., et al. Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience. Medical Council. 2018; 19: 56–60 (in Russ.). https://doi.org/10.21518/2079-701X-2018-19-56-60.

16. Ниязов Р.Р., Драницына М.А., Васильев А.Н., Гавришина Е.В. Биоаналоги: воспроизведение клинического профиля с помощью современных биотехнологий. Сахарный диабет. 2020; 23 (6): 548–60. https://doi.org/10.14341/DM12576.

17. Cortes J., Cescon D.W., Rugo H.S., et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396 (10265): 1817–28. https://doi.org/10.1016/S0140-6736(20)32531-9.

18. Cortes J., Rugo H.S., Cescon D.W., et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022; 387 (3): 217–26. https://doi.org/10.1056/NEJMoa2202809.

19. Trastuzumab deruxtecan (DS-8201a) versus investigator's choice for HER2-low breast cancer that has spread or cannot be surgically removed [DESTINY-Breast04]. NCT03734029. Available at: https://clinicaltrials.gov/study/NCT03734029?term=NCT03734029&rank=1 (accessed 13.08.2025).

20. Modi S., Jacot W., Yamashita T., et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022; 387 (1): 9–20. https://doi.org/10.1056/NEJMoa2203690.

21. Bardia A., Hurvitz S.A., Tolaney S.M., et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021; 384 (16): 1529–41. https://doi.org/10.1056/NEJMoa2028485.

22. Vitsenya M.V., Ageev F.T., Gilyarov M.Yu., et al. Practical recommendations for the correction of cardiovascular toxicity of antitumor drug therapy. Malignant Tumors. 2021; 11 (3s2-2): 78–98 (in Russ.). https://doi.org/10.18027/2224-5057-2021-11-3s2-41.

23. Latipova D.Kh., Andreev V.V., Maslova D.A., et al. Neurological complications of antitumor drug therapy. RUSSCO practical recommendations, part 2. Malignant Tumors. 2023; 13 (3s2): 302–11 (in Russ.). https://doi.org/10.18027/2224-5057-2023-13-3s2-2-302-311.

24. Sakaeva D.D., Borisov K.E., Bulavina I.S. et al. Practical recommendations for the diagnosis and treatment of febrile neutropenia. Malignant Tumors. 2021; 11 (3s2): 55–63 (in Russ.). https://doi.org/10.18027/2224-5057-2021-11-3s2-39.

25. Владимирова Л.Ю., Гладков О.А., Королева И.А. и др. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных. Злокачественные опухоли. 2020; 10 (3s2): 25–38. https://doi.org/10.18027/2224-5057-2021-11-3s2-37.

26. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials. Lancet. 2019; 393 (10179): 1440–52. https://doi.org/10.1016/S0140-6736(18)33137-4.

27. Kolyadina I.V., Andreeva Yu.Yu., Frank G.A., Poddubnaya I.V. Role of biological heterogeneity in recurrent and metastatic breast cancer. Russian Journal of Archive of Patology. 2018; 80 (6): 62–7 (in Russ.). https://doi.org/10.17116/patol20188006162.

28. Smirmova O.V., Borisov V.I., Guens G.P. Immediate and long-term outcomes of drug treatment in patients with metastatic triple negative breast cancer. Malignant Tumours. 2018; 8 (3): 68–77 (in Russ.). https://doi.org/10.18027/2224-5057-2018-8-3-68-77.

29. Felikov I.M., Kashtalap V.V. Risk factors for non-adherence to oral anticoagulant therapy and the potential of their modification in patients with atrial fibrillation: a narrative literature review. Russian Journal of Cardiology. 2024; 29 (10): 6140 (in Russ.). https://doi.org/10.15829/1560-4071-2024-6140.

30. Imran M., Al-Wassia R., Alkhayyat S.S., et al. Assessment of quality of life (QoL) in breast cancer patients by using EORTC QLQ-C30 and BR-23 questionnaires: a tertiary care center survey in the western region of Saudi Arabia. PLoS One. 2019; 14 (7): e0219093. https://doi.org/10.1371/journal.pone.0219093

31. Le Basle Y., Chennell P., Tokhadze N., et al. Physicochemical stability of monoclonal antibodies: a review. J Pharm Sci. 2020; 109 (1): 169–90. https://doi.org/10.1016/j.xphs.2019.08.009.

32. Kumar D., Tomar R.S., Deolia S.K., et al. Isolation and characterization of degradation impurities in docetaxel drug substance and its formulation. J Pharm Biomed Anal. 2007; 43 (4): 1228–35. https://doi.org/10.1016/j.jpba.2006.10.015.

33. Eroles A.A., Bafalluy I.M., Arnaiz J.A. Stability of docetaxel diluted to 0.3 or 0.9 mg/mL with 0.9% sodium chloride injection and stored in polyolefin or glass containers. Am J Health Syst Pharm. 2009; 66 (17): 1565–8. https://doi.org/10.2146/ajhp080482.